ARWR falls after first human results for ARO-DIMER-PA
Arrowhead Pharmaceuticals shares fell over 10% on Tuesday after posting first human results for experimental ARO-DIMER-PA, a shot intended to silence two cholesterol genes with one molecule.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.